

Original Article

Functional study of the effect of phosphatase inhibitors on KCNQ4 channels expressed in *Xenopus* oocytes

Tzu-rong SU¹, Cay-huyen CHEN², Shih-jen HUANG², Chun-yi LEE², Mao-chang SU³, Gwan-hong CHEN⁴, Shuan-yow LI⁴, Jiann-jou YANG⁴, Min-jon LIN^{4,*}

¹Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital, Tong-Kang, Pintong, Taiwan, China; ²Department of Anesthesiology, Buddhist Tzu Chi General Hospital, Taipei branch, Taiwan, China; ³Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan, China; ⁴Department of Biomedical Sciences, Chung Shan Medical University, Taichung, Taiwan, China

Aim: KCNQ4 channels play an important part in adjusting the function of cochlear outer hair cells. The aim of this study was to investigate the effects of ser/thr phosphatase inhibitors on human KCNQ4 channels expressed in *Xenopus laevis* oocytes.

Methods: Synthetic cRNA encoding human KCNQ4 channels was injected into *Xenopus* oocytes. We used a two-electrode voltage clamp to measure the ion currents in the oocytes.

Results: Wild-type KCNQ4 expressed in *Xenopus* oocytes showed the typical properties of slow activation kinetics and low threshold activation. The outward K⁺ current was almost completely blocked by a KCNQ4 blocker, linopirdine (0.25 mmol/L). BIM1 (a PKC inhibitor) prevented the effects of PMA (a PKC activator) on the KCNQ4 current, indicating that PKC may be involved in the regulation of KCNQ4 expressed in the *Xenopus* oocyte system. Treatment with the ser/thr phosphatase inhibitors, cyclosporine (2 μmol/L), calyculin A (2 μmol/L) or okadaic acid (1 μmol/L), caused a significant positive shift in V_{1/2} and a decrease in the conductance of KCNQ4 channels. The V_{1/2} was shifted from -14.6±0.5 to -6.4±0.4 mV by cyclosporine, -18.8±0.5 to -9.2±0.4 mV by calyculin A, and -14.1±0.5 to -0.7±0.6 mV by okadaic acid. Moreover, the effects of these phosphatase inhibitors (okadaic acid or calyculin A) on the induction of a positive shift of V_{1/2} were augmented by further addition of PMA.

Conclusion: These results indicate that ser/thr phosphatase inhibitors can induce a shift to more positive potentials of the activation curve of the KCNQ4 current. It is highly likely that the phosphatase functions to balance the phosphorylated state of substrate protein and thus has an important role in the regulation of human KCNQ4 channels expressed in *Xenopus* oocytes.

Keywords: KCNQ4 channel; phosphatase inhibitor; calyculin A; okadaic acid; protein kinase C; phosphorylation; electrophysiology; *Xenopus* oocyte

Acta Pharmacologica Sinica (2009) 30: 1220–1226; doi: 10.1038/aps.2009.117; published online 24 August 2009

Introduction

KCNQ4, a novel potassium channel, plays a part in regulating the membrane potential and function of various cell types in the body^[1]. The KCNQ4 current is a low-threshold, slow activating and noninactivating current that is expressed in the outer hair cells of the cochlea, brain, and heart. Mutations in KCNQ4 give rise to an inherited syndrome of deafness^[2]. Therefore, the regulatory pathways of KCNQ4 channels play an important role in adjusting the function of outer hair cells. The KCNQ gene subfamily is composed of five K⁺ channels, KCNQ1 to KCNQ5. The KCNQ4 channel was included in the

Kv nomenclature as Kv 7.4 (voltage-gated potassium channel subunit Kv7.4)^[3]. The heteromers of KCNQ2/KCNQ3 underlie the neuronal M-current, which modulates neuronal excitability. Many intracellular messengers, eg, PIP2, IP3, diacylglycerol (DAG), calmodulin, calcineurin, activators/inhibitors of PKC, tyrosine kinases, and myosin light chain kinase, have been reported to modulate M currents^[4–6]. Moreover, the A-kinase-anchoring protein AKAP150, which binds PKC, facilitates the inhibition of KCNQ2 current^[7]. Analysis of recombinant KCNQ2 channels suggests that targeting of PKC through association with AKAP150 is important for inhibition. However, the effect of PKC activation on KCNQ channels is still controversial^[8]. The inhibition of the metabolism of DAG by DAG kinase blockers cannot mimic the effect of muscarinic modulation by muscarinic agonist, and it has been suggested

* To whom correspondence should be addressed.

E-mail mjl@csmu.edu.tw

Received 2009-02-25 Accepted 2009-07-02

that activated PKC and its targets are not essential players in the acute muscarinic modulation of KCNQ channels in mammalian expression systems^[8]. By contrast, the activation of PKC induced a large positive shift in the conductance-voltage curve for KCNQ channels expressed in *Xenopus* oocytes^[9]. The activation of PKC had a different effect on KCNQ channels expressed in mammalian cells and *Xenopus* oocytes, which could be due to the different intracellular environment and basal levels of channel phosphorylation.

The electrophysiological properties of KCNQ4 channels are similar to those of heteromers of KCNQ2/KCNQ3, such as the shifting effect of the conductance-voltage response curve induced by M1 receptor stimulation^[10], but the information about interactions between PKC and KCNQ4 is not clear. PKC, by phosphorylating its target protein and modulating its function, could interact with phosphatases. Protein phosphatases mediate the physiological dephosphorylation of target proteins, an activity that might be expected to reverse the effect induced by PKC. However, the inhibition of phosphatases can sometimes enhance the effect induced by a PKC activator. Therefore, the ser/thr phosphatase inhibitors, cyclosporine, okadaic acid, and calyculin A, were used in this study to investigate the role of phosphatase on the activity of KCNQ4 channels expressed in *Xenopus* oocytes. Our results demonstrated that phosphatase inhibitors induced a shift in the voltage dependence of KCNQ4 channels to more positive potentials. Furthermore, the PKC activator PMA potentiates the effects of okadaic acid and calyculin A in the modulation of KCNQ4 channels. Thus, we propose that endogenous phosphatases play a role in the regulation of KCNQ4 channels and balance the excess activity of PKC in the *Xenopus* oocytes expression system.

Materials and methods

Preparation of RNA

The molecular biological procedures were performed much as previously described^[11]. The plasmid cDNA encoding the human KCNQ4 channel was a generous gift from Prof Thomas J JENTSCH. The cDNA had been previously subcloned into the expression vector pTLN, which contains the 5' and 3' regions of the *Xenopus* β -globin gene to boost expression in oocytes. Plasmid DNA was linearized with *HpaI* (Gibco BRL, USA). For synthesis of cRNA, the mMessage mMachine SP6-polymerase kit (Ambion, USA) was used. The nucleotide sequence of the construct was verified by automated DNA sequencing.

Preparation of *Xenopus* oocytes

Xenopus oocytes were collected from frogs anesthetized in 0.1% sodium bicarbonate solution containing 0.15% tricaine (ethyl 3-aminobenzoate, methanesulfonic acid salt, Sigma-Aldrich). In brief, a lobe of an ovary was surgically removed from the frog's abdominal cavity through a small incision and placed in modified Barth's solution (MBS; in mmol/L: 88 NaCl, 1 KCl, 2.4 NaHCO₃, 0.82 MgSO₄, 0.41 CaCl₂, 0.33 Ca(NO₃)₂, and 15 HEPES-Tris; adjusted to pH 7.6 with NaOH). Isolated oocytes

were defolliculated enzymatically by incubation in collagenase (2 mg/mL, type 1, Gibco, USA) in sterile MBS for 1–2 h followed by several washes in MBS containing 0.1% BSA (Sigma). Stage V–VI oocytes were then incubated and kept overnight at 18 °C. Healthy oocytes were selected, and cRNA (10–15 ng /50 nL) was microinjected into each oocyte using a Nanoject microinjector (Drummond, USA). Injected oocytes were maintained at 18 °C for 2–4 d in MBS supplemented with gentamicin (50 mg/L). The MBS was replaced with fresh medium once a day before electrophysiological recordings. All animal care and experimental procedures were performed according to the guidelines of the Animal Care Committee of the Chung Shan Medical University.

Electrophysiology

The two-electrode voltage clamp (TEVC) technique was used to record whole cell KCNQ4 currents in *Xenopus* oocytes at room temperature (22–26 °C) using an AxoClamp-2B amplifier (Molecular Devices, San Francisco, USA). One of the electrodes was connected to the HS-2x1L headstage to record voltage, while the other was connected to the HS-2x10 MG headstage to record current. Glass electrodes were made from capillary tubing on a vertical electrode puller (Model PP-830, Narishige Scientific Instrument Lab, Japan) and had a tip resistance of 0.5 to 2.0 M Ω when filled with 3 mol/L KCl. Whole-cell K⁺ currents were studied on the oocytes 2–4 d after the cRNA injection. During the experiments, oocytes were placed in an RC-3Z recording chamber (Warner Instruments, USA) and immersed in ND 96 solution consisting of (mmol/L) 96 NaCl, 1 KCl, 1 MgCl₂, 1 CaCl₂, and 5 Hepes; the pH was 7.4. The chamber solution was connected through two 3 mol/L KCl 1% agar-bridged, Ag/AgCl reference electrodes to a virtual ground belonging to a current monitor headstage (VG-2A-x100, Molecular Devices, San Francisco, CA, USA). The condition of each single oocyte was checked before measurements by recording membrane potentials. Only oocytes with membrane potentials below -30 mV were used for current recordings. The data were digitized at 5 kHz and stored using Digidata 1322A (Molecular Devices, San Francisco, USA), and analysis was accomplished with pClamp 9.0 software (Molecular Devices, San Francisco, USA). To determine the conductance-voltage (G–V) relations, a step protocol was employed, whereby the oocytes were clamped at -80 mV for 3 s and depolarized at +60 mV with 20 mV increments to -100 mV, followed by a tail pulse at -30 mV for 2 s.

Data analysis

The tail current protocol was used to generate steady-state activation curves (conductance-voltage curves), which were fitted to a two-state Boltzmann function as follows

$$I_{\text{tail}}(V_m) = I_{\text{tail}(\text{max})} / \{1 - \exp[(V_{1/2} - V_m)/k]\}$$

where $V_{1/2}$ is the voltage that produces half-maximal activation of conductance, V_m is the membrane potential, and k is the slope factor. $I_{\text{tail}(\text{max})}$ is the maximal tail current amplitude. Data are presented as means \pm SEM. Statistical significance was determined using Student's *t* test with one-way analysis of

variance (ANOVA), and P values < 0.05 were taken to indicate statistically significant difference.

Chemicals

PMA (phorbol 12-myristate 13-acetate), cyclosporine, okadaic acid and calyculin A were obtained from LC Laboratories (USA). BIM1 (bisindolylmaleimide I) was obtained from Calbiochem (San Diego, CA, USA). Linopirdine was obtained from Sigma (St Louis, MO, USA). PMA, okadaic acid and calyculin A were dissolved as stock solutions in dimethylsulfoxide (DMSO). Linopirdine was dissolved in 0.1 mol/L HCl as a 25 mmol/L stock solution.

Results

Human KCNQ4 currents in *Xenopus* oocytes

The KCNQ4-expressed oocytes were voltage clamped at -60 mV and stepped to potentials ranging from -80 to $+60$ mV, which produced slow-activated and low-threshold currents as shown in Figure 1A (upper traces). Application of linopirdine (0.25 mmol/L), a blocker of KCNQ4, to the external bath solution completely abolished the K^+ outward current (Figure 1B). The inhibitory effect of linopirdine was reversible by washout (Figure 1C). Figure 1D shows the current-voltage curves of no injection, RNase-free water and KCNQ4 cRNA-injected oocytes. Only the KCNQ4 cRNA group currents show sensitivity to linopirdine. The time course of the peak tail current amplitudes is shown in Figure 1E. The application of linopirdine and washout are indicated by arrows. There was very little run-down of KCNQ4, as indicated by the control curve (without treatment).

Effect of PKC activator on the KCNQ4 current

PKC is an important regulator of KCNQ channels, as shown in previous work^[9]. To test whether activation of PKC leads to a functional change of the KCNQ4 current in a *Xenopus* oocyte model system, PMA (a PKC activator) and BIM1 (a PKC inhibitor) were used in this study. Bath application of PMA (2 μ mol/L) caused a significant inhibitory effect on the amplitude of the KCNQ4 currents (Figure 2A) and a shift in $V_{1/2}$ (half-maximum of the conductance-voltage curve) to more positive potentials (Figure 2C). The $V_{1/2}$ before and after PMA treatment are from -17.7 ± 0.9 mV to -6.5 ± 0.7 mV ($P < 0.05$, $n = 15$). The time course of the tail current amplitudes showed that the effect of PMA is reversible by washout (Figure 2D). An inactive form of PMA, α -PMA, was found to exert an insignificant effect on the $V_{1/2}$ (-18.3 ± 0.9 mV to -16.4 ± 1.2 mV, $n = 3$). Moreover, pretreatment with the PKC inhibitor BIM1 (2 μ mol/L) significantly attenuated the positive shift of $V_{1/2}$ of KCNQ4 induced by PMA. There was no significant difference between the steady-state conductance-voltage curves of BIM1 and BIM1 plus PMA (Figure 2B and 2E). These results suggested that the effect of PMA on the KCNQ4 channel was through the activation of PKC.

Effect of phosphatase inhibitors on the KCNQ4 current

Since the inhibition of phosphatase would maintain a higher




Figure 1. The expressed currents of KCNQ4 were blocked by the addition of linopirdine on *Xenopus* oocytes. (A) Typical current traces were recorded from an oocyte cell expressing KCNQ4 channels with a voltage step protocol as follows: the oocyte was clamped at -60 mV for 3 s, and the channel was activated by 2-s command steps from -100 mV to $+60$ mV in 10-mV increments, followed by a 1-s step to -30 mV. The calibration scale of all current traces is in the upper right corner of (A): 2 s and 1 μ A. The calibration scale of the voltage step protocol is shown between (A) and (B): 2 s and 50 mV. (B) The expressed KCNQ4 current was almost completely blocked by the application of linopirdine (0.25 mmol/L) after 5 min. (C) This inhibitory effect of linopirdine on the KCNQ4 current was reversible by washout. (D) The summarized curves of tail current-voltage relationships in the absence (\bullet) and presence (\square) of linopirdine. The control curves, with oocytes of RNase-free water injection (\circ) and without injection (\triangle) are also shown for comparison. (E) Time course effect of linopirdine on KCNQ4 tail-current (\bullet). Treatment with linopirdine and washout are indicated with arrows. The control curve (without chemical treatment; \circ) showed little run-down during the 50-min recording. The time course of the tail-current amplitude was measured at a tail potential of -30 mV (from a step command of 30 mV).




Figure 2. BIM1, a PKC inhibitor, can antagonize the effect of PMA on KCNQ4 channels. (A) The amplitudes of control KCNQ4 currents (upper traces in A) were inhibited by the application of PMA (2 μ mol/L) (bottom traces in A). (B) The inhibitory effect of PMA on the KCNQ4 current was attenuated by pretreatment with BIM1 (2 μ mol/L) (upper traces: BIM1 alone; bottom traces: BIM1+PMA). The voltage step protocol of (A) and (B) is as indicated in the middle of (A). Calibration scale of all current traces: 2 s and 1 μ A. Calibration scale of the voltage step protocol: 2 s and 50 mV. (C) The midpoint potential of the conductance-voltage curve ($V_{1/2}$) was shifted significantly to a more positive value after treatment with PMA (before PMA: \bullet ; after PMA: \circ). (D) Representative time courses of KCNQ4 tail-current during application of 2 μ mol/L PMA (\bullet) or vehicle (\circ). (E) The shift effect of $V_{1/2}$ produced by PMA was attenuated by pretreatment with BIM1 (BIM1 alone: \blacktriangle ; BIM1+PMA: \triangle). $V_{1/2}$ was obtained from the conductance-voltage curves, which were fitted using a two-state Boltzmann equation as described in the Materials and Methods.

level of the phosphorylation of substrate proteins, the effect of ser/thr phosphatase inhibitors might increase the phosphorylation level of KCNQ4 channels. To test whether phosphatase inhibitors (cyclosporine, calyculin A, and okadaic acid) could cause changes in the electrophysiological properties of channels, we applied these phosphatase inhibitors to KCNQ4-

expressed oocytes. Bath administration of cyclosporine (2 μ mol/L) for 10 min produced a significant inhibitory effect on current amplitude (Figure 3A) and a positive shift of $V_{1/2}$ (from -14.6 ± 0.5 to -6.4 ± 0.4 mV; $n=5$) (Figure 3B). Similar results were also obtained from the application of calyculin A (2 μ mol/L) and okadaic acid (1 μ mol/L). Typical current traces are shown




Figure 3. Effect of phosphatase inhibitor cyclosporine (2 μ mol/L) on the KCNQ4 current expressed in *Xenopus* oocytes. (A) The control KCNQ4 currents (upper current traces) were significantly inhibited by the addition of cyclosporine (2 μ mol/L; lower current traces). Calibration scale of current traces: 2 s and 1 μ A (upper right corner). Calibration scale of voltage step protocol: 2 s and 50 mV (between two current traces). (B) The $V_{1/2}$ was shifted significantly to a more positive value after the treatment with cyclosporine (control: \bullet ; cyclosporine treatment: \circ).

in Figures 4A to C for calyculin A (A, before treatment; B, after calyculin A; C, Calyculin A+PMA) and in Figures 4D to F for okadaic acid (D, before treatment; E, after okadaic acid; F, okadaic acid+PMA). The peak tail current amplitudes of KCNQ4 (at -20 mV) were inhibited by calyculin A (from $2.05 \pm 0.08 \mu\text{A}$ decrease to $1.45 \pm 0.13 \mu\text{A}$; $P < 0.05$, $n=5$) and okadaic acid (from $1.64 \pm 0.05 \mu\text{A}$ decrease to $1.2 \pm 0.04 \mu\text{A}$; $P < 0.05$, $n=4$). The inhibition effects of calyculin A and okadaic acid were significantly enhanced by the subsequent addition of $2 \mu\text{mol/L}$ PMA (from $1.45 \pm 0.13 \mu\text{A}$ to $0.76 \pm 0.07 \mu\text{A}$ for calyculin A; from $1.2 \pm 0.04 \mu\text{A}$ to $0.80 \pm 0.04 \mu\text{A}$ for okadaic acid). Detailed information on the half-activation voltage ($V_{1/2}$) can be obtained through the analysis of conductance-voltage (G - V) curves. The effects of calyculin A and okadaic acid on the conductance-voltage (G - V) curves of KCNQ4 are shown in Figure 4G and 4H, respectively. Both calyculin A and okadaic acid produced a shift in the voltage of half-maximal activation ($V_{1/2}$) to a more positive potential (calyculin A: from -18.8 ± 0.5 to -9.2 ± 0.4 mV; $P < 0.05$, $n=5$; okadaic acid: from -14.1 ± 0.5 to -0.7 ± 0.6 mV; $P < 0.05$, $n=4$). Subsequently, the application of PMA after phosphatase inhibitor (calyculin A or okadaic acid) treatment induced a further positive shift in the $V_{1/2}$ of KCNQ4 channels.

In other words, the change in electrophysiological parameters induced by a combined treatment with PKC activator (PMA) and phosphatase inhibitor on KCNQ4 was greater than that of either alone.

Discussion

In a previous study, Gamper *et al*^[12] found that the inhibition of tyrosine phosphatase reduces the conductance of KCNQ channels expressed in transfected Chinese hamster ovary cells. In the present study, we demonstrate that ser/thr phosphatase inhibitors can inhibit the conductance of KCNQ4 channels and shift the $V_{1/2}$ (midpoint of conductance-voltage curve) to a more positive potential in a *Xenopus* oocyte expression system. This implies that the endogenous phosphatase is required for maintaining KCNQ4 channel activities in the *Xenopus* expression system. Moreover, the combination treatment of PMA (a PKC activator) and a phosphatase inhibitor showed a greater inhibitory effect than that of each alone, indicating that the most important inhibition in channel activity was due to the enhanced phosphorylation of KCNQ4. Thus, we propose that KCNQ4 channel activity is regulated by a balance between phosphorylation and dephosphorylation by the protein kinase




Figure 4. Effects of phosphatase inhibitors (calyculin A and okadaic acid) and the combination of phosphatase inhibitor with PMA on the KCNQ4 currents. Typical recording traces of KCNQ4 are shown in figures (A)–(F). The traces in Figures (A)–(C) and Figures (D)–(F) are recorded from the same oocyte, respectively. Tail current amplitudes of control KCNQ4 (A) were significantly inhibited by the addition of $2 \mu\text{mol/L}$ calyculin A (B) and, subsequently, addition of PMA ($2 \mu\text{mol/L}$) caused a further decrease in the current amplitudes (C). The effect of okadaic acid ($1 \mu\text{mol/L}$) on the KCNQ4 current amplitudes was similar to that of calyculin A (D: before the treatment with okadaic acid; E: after the treatment with okadaic acid; F: okadaic acid plus $2 \mu\text{mol/L}$ PMA). All static values of current amplitudes are shown in the results section. Calibration scales of all current traces are shown in the upper right corners of (A) and (D): 2 s and $2 \mu\text{A}$. The voltage-step protocol is shown below (A). Figures (G) and (H) show conductance-voltage (G - V) curves of KCNQ4. Both calyculin A and okadaic acid can produce a positive shift of the half voltage of the G - V curve (●: before the treatment in Figs G and H; △: after treatment with calyculin A in Figure G; ○: after treatment with okadaic acid in Figure H). Subsequently, the further addition of PMA after the phosphatase inhibitor can produce a more positive shift of $V_{1/2}$ (□: calyculin A plus PMA and okadaic acid plus PMA in Figures G and H, respectively).

and phosphatase.

PMA, a PKC activator, has been shown to produce a positive shift in the voltage dependence of KCNQ2 channels, while chelerythrine, a PKC inhibitor, attenuated the shift induced by muscarinic stimulation in the *Xenopus* oocytes expression system^[9]. In results consistent with the previous studies, we also found that the effect of PMA on the KCNQ4 channels was antagonized by pretreatment with a PKC inhibitor, BIM1. Interestingly, PKA can reduce the effects of elevated Ca^{2+} on run-down of expressed KCNQ4 channels^[13]. The different modulating effect by PKA and PKC may be due to the PKC phosphorylation sites that do not overlap with those phosphorylated by PKA.

A detailed characterization of the sites of phosphorylation of KCNQ2/KCNQ3 channels has been identified by mass spectrometry^[14]. The phosphorylation sites are the S4-S5 intracellular loop and the domain for tetramerization in the C terminus^[15, 16]. Taken together, these studies suggest that the cytoplasmic phosphorylation sites of KCNQ channels may play an important role in channel inhibition through the activation by PKC. However, it has been reported that the stimulation of the diacylglycerol-PKC pathway does not play an essential role in the acute modulation of the KCNQ channel in a mammalian expression system^[8]. One possible explanation for the different results between *Xenopus* oocytes and mammalian expression systems is that a DAG-insensitive PKC (atypical PKC) exists in mammalian cells; another possibility is that the amount of active PKC or/and auxiliary protein differs depending on the intracellular environment. A recent study concerning the adaptor/auxiliary protein AKAP150 has found that it can interact simultaneously with both KCNQ2 and PKC, promoting the PKC-induced serine phosphorylation of KCNQ2 in a mammalian expression system^[7]. A mutant form of AKAP150 that is unable to bind PKC attenuates the current inhibition by M1-receptor activation. These observations support the hypothesis that the auxiliary protein AKAP150 is required for PKC-induced inhibition of KCNQ channels by M1-receptor activation.

Another possible way to modulate the activity of KCNQ channels is with phosphatases. The dephosphorylation of phosphorylated KCNQ proteins may be due to an initial stimulation of the membrane phosphatases, which would be expected to antagonize the inhibitory effect induced by PKC stimulation on KCNQ channels. In this case, the inhibition of phosphatase activity accounts for the altered balance between kinases and phosphatases, which in turn probably contributes to increasing the phosphorylated state of KCNQ4. Phosphatase inhibitors would be expected to cause a positive shift in $V_{1/2}$ potentials if the endogenous phosphatase activity is present in this model system. Among the phosphatases, protein phosphatases 1 and 2A are major ser/thr protein phosphatases involved in many cellular events, including regulation of the cell cycle of *Xenopus laevis* oocytes^[17-19]. Cyclosporine, okadaic acid, and calyculin A are potent inhibitors of protein phosphatase. In this study, we show that treatment of *Xenopus* oocytes expressing human KCNQ4 with

cyclosporine, okadaic acid, or calyculin A produced a positive shift of $V_{1/2}$. These results indicate that endogenous phosphatase may modulate the human KCNQ4 channels expressed in *Xenopus* oocytes. A combination treatment of PMA plus phosphatase inhibitor produced a more positive shift of $V_{1/2}$ than that of phosphatase inhibitor alone, indicating that the maintenance of a higher level of the phosphorylated proteins would result in a more dramatic positive shift in the $V_{1/2}$ of KCNQ4 channels. Although our studies did not reveal the phosphorylation or dephosphorylation sites of KCNQ4, the inhibition of the dephosphorylation of phosphorylated proteins by phosphatase inhibitors did cause a significant change in the channel properties of KCNQ4. In summary, we demonstrated that phosphatase inhibitors induce a positive shift of the activation curve and an inhibition of channel conductance in human KCNQ4 expressed in *Xenopus* oocytes. Phosphatase may interact with substrates such as KCNQ4 or other auxiliary proteins to balance the phosphorylation level induced by protein kinase and thus play an important role in the regulation of KCNQ4 channel activity in a *Xenopus* oocyte expression system.

Acknowledgments

Prof Thomas J JENTSCH is acknowledged for kindly supplying human KCNQ4 cDNA. These studies were supported by grants from the National Science Council, Taiwan (NSC 96-2320-B-040-013), CSMU-TSMH-097-007, and TCRD-TPE-95-39.

Author contribution

Tzu-rong SU performed research. Cay-huyen CHEN analyzed data and preparations. Shih-jen HUANG analyzed data and reagents. Chun-yi LEE did part of preparations. Mao-chang SU performed TEVC recording. Gwan-hong CHEN performed oocytes isolation and TEVC recording. Shuan-yow LI, Jian-njou YANG wrote part of introduction. Min-jon LIN wrote the paper and performed part of research.

References

- 1 Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, *et al*. KCNQ4, a K⁺ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. *Proc Natl Acad Sci USA* 2000; 97: 4333-8.
- 2 Kubisch C, Schroeder BC, Friedrich T, Lutjohann B, El-Amraoui A, Marlin S, *et al*. KCNQ4, a novel potassium channel expressed in sensory outer hair cells is, mutated in dominant deafness. *Cell* 1999; 96: 437-46.
- 3 Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, *et al*. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. *Pharmacol Rev* 2003; 55: 583-6.
- 4 Marrion NV. Control of M-current. *Annu Rev Physiol* 1997; 59: 483-504.
- 5 Loussouarn G, Park KH, Belloq C, Baro I, Charpentier F, Escande D. Phosphatidylinositol-4,5-bisphosphate, PIP₂, controls KCNQ1/KCNE1 voltage-gated potassium channels: a functional homology between voltage-gated and inward rectifier K⁺ channels. *EMBO J* 2003; 22:

- 5412–21.
- 6 Zhang H, Craciun LC, Mirshahi T, Rohacs T, Lopes CM, Jin T, *et al*. PIP₂ activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. *Neuron* 2003; 37: 963–75.
 - 7 Hoshi N, Zhang JS, Omaki M, Takeuchi T, Yokoyama S, Wanaverbecq N, *et al*. AKAP150 signaling complex promotes suppression of the M-current by muscarinic agonists. *Nat Neurosci* 2003; 6: 564–571.
 - 8 Suh BC, Hille B. Does diacylglycerol regulate KCNQ channels? *Pflügers Archive Eur J Physiol* 2006; 453: 293–301.
 - 9 Nakajo K, Kubo Y. Protein kinase C shifts the voltage dependence of KCNQ/M channels expressed in *Xenopus* oocytes. *J Physiol* 2005; 569: 59–74.
 - 10 Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. *Nat Rev Neurosci* 2005; 6: 850–62.
 - 11 Su CC, Li SY, Yang JJ, Su MC, Lin MJ. Studies of the effect of ionomycin on the KCNQ4 channel expressed in *Xenopus* oocytes. *Biochem Biophys Res Commun* 2006; 348: 295–300.
 - 12 Gamper N, Stockland JD, Shapiro MS. Subunit-specific modulation of KCNQ potassium channels by Src tyrosine kinase. *J Neurosci* 2003; 23: 84–95.
 - 13 Chambard JM, Ashmore JF. Regulation of the voltage-gated potassium channel KCNQ4 in the auditory pathway. *Pflüger Arch Eur J Physiol* 2005; 450: 34–44.
 - 14 Surti TS, Huang L, Jan YN, Jan LY, Cooper EC. Identification by mass spectrometry and functional characterization of two phosphorylation sites of KCNQ2/KCNQ3 channels. *Proc Natl Acad Sci USA* 2005; 102: 17828–33.
 - 15 Schwake M, Jentsch TJ, Friedrich T. A carboxy-terminal domain determines the subunit specificity of KCNQ K⁺ channel assembly. *EMBO Rep* 2003; 4: 76–81.
 - 16 Howard RJ, Clark KA, Holton JM, Minor DL Jr. Structural insight into KCNQ (Kv7) channel assembly and channelopathy. *Neuron* 2007; 53: 663–75.
 - 17 Walker DH, DePaoli-Roach AA, Maller JL. Multiple roles for protein phosphatase 1 in regulating the *Xenopus* early embryonic cell cycle. *Mol Biol Cell* 1992; 3: 687–98.
 - 18 Lee TH. The role of protein phosphatase type-2A in the *Xenopus* cell cycle: initiation of the G2/M transition. *Semin Cancer Biol* 1995; 6: 203–9.
 - 19 Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signaling. *Biochem J* 2001; 353: 417–39.